Printer Friendly

Lasofoxifene shown to sharply reduce incidence of breast cancer.

SAN ANTONIO -- The investigational selective estrogen-receptor modulator lasofoxifene is shaping up as a PEARL of a drug for the prevention of breast cancer.

Lasofoxifene (Fablyn) slashed the incidence of estrogen receptor-positive breast cancer by 81%, compared with placebo, over a 5-year period in the 8,556-women, phase III PEARL (Postmenopausal Evaluation and Risk Reduction With Lasofoxifene) trial, Andrea Z. LaCroix, Ph.D., reported at the San Antonio Breast Cancer Symposium.

That's a considerably more dramatic preventive effect than the roughly 50% reductions seen in earlier placebo-controlled trials of tamoxifen and raloxifene, the two approved agents for primary prevention of breast cancer, added Dr. LaCroix, a professor of epidemiology at the University of Washington, Seattle.

Reduction of estrogen receptor-positive breast cancer was a coprimary end point in PEARL, together with nonvertebral fractures, which were decreased by a highly significant 24% in women randomized to lasofoxifene at 0.5 mg/day.

The PEARL participants (aged 59-80 years) were enrolled in 32 countries. All had osteoporosis at entry. They were randomized to placebo or lasofoxifene at 0.25 or 0.5 mg/day.

During 5 years of follow-up, 21 women in the placebo arm developed estrogen receptor-positive breast cancer, as did 11 in the lower-dose and 4 in the higher-dose lasofoxifene arms. The incidence was 0.3 cases per 1,000 patient-years in women on lasofoxifene at 0.5 mg/day, 0.9 cases per 1,000 patient-years with lasofoxifene at 0.25 mg/day, and 1.9 cases per 1,000 patient-years with placebo.

Women on lasofoxifene at 0.5 mg/day had a 35% reduction in breast biopsies, compared with the 2.8% incidence in the placebo arm. As expected, the SERM had no effect on the rate of estrogen receptor-negative breast cancers. The risk of ductal carcinoma in situ was similarly unaffected.

Dr. LaCroix noted that lasofoxifene had its greatest breast cancer reduction benefit among women with above-average levels of estradiol. Other benefits included a reduction of 42% in vertebral fractures, a decrease of 32% in major coronary heart disease events, and a 36% reduction in strokes.

The chief risk associated with the SERM was a twofold increase in venous thromboembolic events (from 0.4% over 5 years in the placebo arm to 0.8% with 0.5 mg lasofoxifene).

In September 2008, the Food and Drug Administration's Reproductive Health Advisory Committee recommended approval of Pfizer Inc.'s application for an indication for lasofoxifene at the 5-mg dose for treatment of osteoporosis. One oncologist in the San Antonio audience shrugged off Pfizer's failure to seek an additional indication for breast cancer prevention, noting that once lasofoxifene is approved for osteoporosis, physicians will readily be able to prescribe the drug in postmenopausal women for breast cancer prevention as well.

Dr. LaCroix disclosed that she is on the advisory boards for Pfizer, Sanofi-Aventis, and Procter & Gamble Co.


Denver Bureau
COPYRIGHT 2009 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:WOMEN'S HEALTH
Author:Jancin, Bruce
Publication:Internal Medicine News
Geographic Code:1USA
Date:Jan 15, 2009
Previous Article:Breast density predicts drug's preventive benefit.
Next Article:Soy matches HT for menopause symptoms.

Related Articles
Milk seems to guard against breast cancer.
In developed and developing countries, breast cancer risk is reduced by 4% for each year of breastfeeding. (Digests).
Update on lifestyle modification for prevention of breast cancer: a 30%-40% reduction feasible.
Vitamin D guards against breast, colorectal cancers.
Most common breast cancer drops a dramatic 15%.
Fall in breast cancer incidence after reduction in use of HRT in Australia.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters